Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Curr Neurovasc Res ; 2024 01 26.
Artículo en Inglés | MEDLINE | ID: mdl-38288841

RESUMEN

BACKGROUND: Major depression has a complex and multifactorial etiology constituted by the interaction between genetic and environmental factors in its development. OBJECTIVE: The aim of this study was to evaluate the effects of sodium butyrate (SD) on epigenetic enzyme alterations in rats subjected to animal models of depression induced by maternal deprivation (MD) or chronic mild stress (CMS). METHODS: To induce MD, male Wistar rats were deprived of maternal care during the first 10 days of life. To induce CMS, rats were subjected to the CMS for 40 days. Adult rats were then treated with daily injections of SD for 7 days. Animals were subjected to the forced swimming test (FST), and then, histone deacetylase (HDAC), histone acetyltransferase (HAT), and DNA methyltransferase (DNMT) activities were evaluated in the brain. RESULTS: MD and CMS increased immobility time in FST and increased HDAC and DNMT activity in the animal brains. SD reversed increased immobility induced by both animal models and the alterations in HDAC and DNMT activities. There was a positive correlation between enzyme activities and immobility time for both models. HDAC and DNMT activities also presented a positive correlation between themselves. CONCLUSION: These results suggest that epigenetics can play an important role in major depression pathophysiology triggered by early or late life stress and its treatment.

2.
Schizophrenia (Heidelb) ; 9(1): 69, 2023 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-37798312

RESUMEN

One of the most robust neurochemical abnormalities reported in patients with schizophrenia is an increase in dopamine (DA) synthesis and release, restricted to the dorsal striatum (DS). This hyper functionality is strongly associated with psychotic symptoms and progresses in those who later transition to schizophrenia. To understand the implications of this progressive neurobiology on brain function, we have developed a model in rats which we refer to as EDiPs (Enhanced Dopamine in Prodromal schizophrenia). The EDiPs model features a virally mediated increase in dorsal striatal (DS) DA synthesis capacity across puberty and into adulthood. This protocol leads to progressive changes in behaviour and neurochemistry. Our aim in this study was to explore if increased DA synthesis capacity alters the physiology of DA release and DS connectivity. Using fast scan cyclic voltammetry to assess DA release we show that evoked/phasic DA release is increased in the DS of EDiPs rats, whereas tonic/background levels of DA remain unaffected. Using quantitative immunohistochemistry methods to quantify DS synaptic architecture we show a presynaptic marker for DA release sites (Bassoon) was elevated within TH axons specifically within the DS, consistent with the increased phasic DA release in this region. Alongside changes in DA systems, we also show increased density of vesicular glutamate transporter 1 (VGluT1) synapses in the EDiPs DS suggesting changes in cortical connectivity. Our data may prove relevant in understanding the long-term implications for DS function in response to the robust and prolonged increases in DA synthesis uptake and release reported in schizophrenia.

3.
Exp Gerontol ; 113: 209-217, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30304709

RESUMEN

Aging is a complex biological process. Epigenetic alterations have been related to both aging and memory decline. Included amongst these alterations is histone acetylation, which may play a crucial role in aging. Thus, the aims of the present study were to standardize the animal model of d-galactose (d-gal), and to evaluate the effects caused by sodium butyrate (SB), which is a histone deacetylase inhibitor on memory, the modulation of histone deacetylases (HDACs), and also DNA damage in 2, 6 or 16-month-old Wistar rats which were subjected to administrations of d-gal. To help choose the best dose of d-gal for the induction of the aging model, we performed a dose-response curve (100, 200 or 300 mg/kg). d-Gal was administered orally to the 2-month-old rats for a period of 30 days. After this, d-gal (200 mg/kg) or water were administered to the 2, 6 or 16-month-old rats for a period of 30 days. On the 24th day, treatment was started with SB (600 mg/kg) intraperitoneally, for a period of 7 days. SB was able to reverse the damage to habituation memory caused by d-gal in the 2 and 6-month-old rats, but was unable to reverse the damage in the 16 month-old animals. In addition, SB was able to reverse the damage caused by natural aging in the 16-month-old animals. In the inhibitory avoidance task, SB improved the damage caused by d-gal in the 2, 6 and 16-month-old animals and had the same result against the effects of natural aging in the 16-month-old rats. Moreover, d-gal caused an increase in the level of HDACs activity in the 16-month-old animals, and SB was able to reverse this effect in the frontal cortex and hippocampus. The 16-month-old animals showed an increase in the frequency of DNA damage in peripheral blood, and SB was able to reduce this damage. Moreover, d-gal caused an increase in the index and frequency of DNA damage in the 2 and 6-month-old animals, and treatment with SB was able to prevent this damage. Thus, the present study showed the protective effects of SB on the memory of naturally aged and d-gal induced aging in rats. Therefore, the present study shows new findings for the use of SB in aging.


Asunto(s)
Envejecimiento/efectos de los fármacos , Ácido Butírico/farmacología , Galactosa/farmacología , Inhibidores de Histona Desacetilasas/farmacología , Memoria/efectos de los fármacos , Animales , Encéfalo/efectos de los fármacos , Daño del ADN/efectos de los fármacos , Modelos Animales de Enfermedad , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratas , Ratas Wistar
4.
Curr Neurovasc Res ; 11(4): 359-66, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25233278

RESUMEN

It is known that cognitive processes, such as learning and memory, are affected in depression. Several authors have described histone deacetylase (HDAC) inhibitors as a class of drugs that improves long-term memory formation. The current study examined the effects of maternal deprivation (MD) and chronic mild stress (CMS), which have been shown as animal models of depression, and the effects of sodium butyrate (SB), a HDAC inhibitor, on recognition memory. Considering that neurotrophic factors has been pointed as a key event involved with cognition and depressive disorder, levels of neurotrophic factors (BDNF, NGF and GDNF) were also investigated. MD and CMS induced depressive-like behavior in the forced swimming test (FST) and memory impairment in the object recognition (OR) test, without altering locomotor activity of rats. In addition, SB was able to reverse the stress-induced neurotrophic factors decrease and reversed memory impairment. The results indicate that the stress both at early and later stage of life may induce cognitive impairment in animals and neurotrofic factors (BDNF, NGF and GDNF) levels decrease. SB treatment improved the recognition memory and reversed the neurotrophins levels decreased in the hippocampus of rats submitted to the MD and CMS models. Together, our results reinforce the notion that SB displays a specific antidepressant profile and improve cognition in MD and CMS rats that may be, at least in part, due to its upregulation of neurotrophic factors.


Asunto(s)
Antidepresivos/uso terapéutico , Ácido Butírico/uso terapéutico , Trastornos del Conocimiento/tratamiento farmacológico , Depresión/tratamiento farmacológico , Depresión/etiología , Privación Materna , Estrés Psicológico/complicaciones , Análisis de Varianza , Animales , Trastornos del Conocimiento/etiología , Modelos Animales de Enfermedad , Conducta Exploratoria/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Masculino , Ratas , Ratas Wistar , Reconocimiento en Psicología/efectos de los fármacos , Estrés Psicológico/patología , Natación/psicología
5.
Curr Neurovasc Res ; 9(1): 47-57, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22272765

RESUMEN

The present study aims to investigate the effects of protein kinase C using the inhibitor Tamoxifen (TMX) on oxidative stress in a rat animal model of mania induced by d-amphetamine (d-AMPH). In the reversal model, d-AMPH or saline (Sal) were administered to rats for 14 days, and between days 8-14, rats were treated with TMX or Sal. In the prevention model, rats were pretreated with TMX or Sal, and between days 8-14, d-AMPH or Sal were administrated. In both experiments locomotor activity and risk-taking behavior were assessed by open-field test and oxidative stress was measured in prefrontal, amygdala, hippocampus and striatum. The results showed that TMX reversed and prevented d- AMPH-induced behavioral effects. In addition, the d-AMPH administration induced oxidative damage in both structures tested in two models. The TMX was able to reverse and prevent this impairment, however in a way dependent of cerebral area and technique evaluated. These findings reinforce the hypothesis that PKC play an important role in the pathophysiology of BD and the need for the study of inhibitors of PKC as a possible target for treatment the BD.


Asunto(s)
Trastorno Bipolar/metabolismo , Inhibidores Enzimáticos/farmacología , Estrés Oxidativo/efectos de los fármacos , Proteína Quinasa C/metabolismo , Animales , Antimaníacos/farmacología , Conducta Animal/efectos de los fármacos , Trastorno Bipolar/inducido químicamente , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Dextroanfetamina/toxicidad , Modelos Animales de Enfermedad , Inhibidores de Captación de Dopamina/toxicidad , Masculino , Actividad Motora/efectos de los fármacos , Ratas , Ratas Wistar , Tamoxifeno/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...